Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × niraparib × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urogenital Neoplasms 1 Prostatic Neoplasms 1 Prostatic Diseases 1 Ovarian Neoplasms 1 Ovarian Diseases 1 Neoplasms 1 Lymphoma 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Gonadal Disorders 1 Genital Neoplasms, Male 1 Genital Neoplasms, Female 1 Genital Diseases, Male 1 Genital Diseases, Female 1 Endocrine System Diseases 1 Endocrine Gland Neoplasms 1 Adnexal Diseases 1

Interventions

Cyclophosphamide 446 Rituximab 405 Etoposide 225 Vincristine 217 Doxorubicin 204 Filgrastim 201 Prednisone 178 Cytarabine 160 Radiotherapy 152 fludarabine phosphate 147 Methotrexate 137 Peripheral Blood Stem Cell Transplantation 130 Melphalan 128 fludarabine 115 Busulfan 100 Dexamethasone 93 Tacrolimus 75 Carmustine 74 Granulocyte Colony-Stimulating Factor 73 Mycophenolic Acid 71 Gemcitabine 66 Bortezomib 65 Antilymphocyte Serum 65 Bendamustine Hydrochloride 63 Whole-Body Irradiation 62 Lenalidomide 62 Cyclosporine 61 Ifosfamide 58 sargramostim 51 Methylprednisolone 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡